Evaluation of a pre-co-seasonal and a perennial schedule of a single multiallergen depigmented-polymerized subcutaneous immunotherapy in paediatric patients.

AIM: Compare a pre-co-seasonal with a perennial schedule using an undiluted mixture of a depigmented-polymerized grass/Olea europaea immunotherapy (2,000 DPP/mL) in pediatric patients with rhinitis/rhinoconjunctivitis with or without controlled asthma. MATERIAL AND METHODS: Primary objective was to determine the non-superiority of a perennial compared to a pre-co-seasonal schedule by means of Paediatric/Adolescent Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ/AdolRQLQ). Secondary objectives were Paediatric Asthma/Caregiver´s Quality of Life Questionnaire (PAQLQ/PACQLQ) Asthma Control Test (ACT), Visual Analogue Scale global assessment of allergic disease (VAS), use of resources and immunological response. All variables were compared during the pollen season (April-June) without (2015) and with (2016) immunotherapy. RESULTS: Forty patients were included in the study of which 29 patients were assigned to the perennial and 11 to the pre-co-seasonal schedule. During 2016 pollen season a significant improvement in the PRQLQ/AdolRQLQ, PAQLQ/AdolAQLQ, ACT and VAS score were observed both in perennial and pre-co-seasonal schedule group. No significant differences were seen between treatment schedules for PRQLQ/AdolRQLQ, PAQLQ/AdolAQLQ and ACT scores comparing both pollen seasons. A significant increase in sIgG4 and reduction in the number of rescue medications used and number of patients who needed visit to any specialist was observed in both treatment schedules during 2016 pollen season. No relevant differences were found in the safety profile of any treatment schedule. DISCUSSION: Treatment with undiluted mixture of a depigmented-polymerized Grass/Olea europaea allergen immunotherapy has proven to be effective both using a perennial and a pre-co-seasonal schedule and therefore suitable for polyallergic patients.

[Sensitization to Olea europaea in a patients group of Mexico City]. / Sensibilización a Olea europaea en un grupo de pacientes de la Ciudad de México.

RATIONALE: Olea europaea (olive) which is original from Europe, was introduced to Mexico by the Spaniards in the 16th century. In 1777 olive farming was prohibited, and plantations were destroyed. At present there are only few trees in Southern Mexico City. The aim of this study is to investigate sensitization to Olea europaea, clinical features, IgE levels, and concurrent pollen sensitizations in a group of Mexican patients. METHOD: A retrospective chart review of all patients (n=232) with pollen allergy, between August 2003 and August 2004, in a medical office. RESULTS: The sensitization to Olea europaea was found in 41.5% (96). The median IgE levels was 387.2 UI/ml. Symptoms were: 95.8% with allergic rhinitis, 58.3% asthma, 66.6% chronic sinusitis, 36.4% otitis media with effusion, 29.1% allergic conjunctivitis, 16.6% atopic dermatitis, 16.6% oral allergy syndrome, mainly related to apple and strawberries; and 4.5% paranasal polyposis. Positive skin prick tests to Olea europaea were higher on April (27.2%), and lower on November (2.5%). CONCLUSION: Olea europaea is an important sensitizer in Mexico City. Cross-reaction to other pollens belonging to Oleaceae family, possibly Osmanthus americanus, could explain monosensitization to olive tree.